Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved the extended use of Pfizer's pneumococcal conjugate vaccine Prevnar 13 to prevent pneumonia.
Subscribe to our email newsletter
Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) has been recommended as a single dose for use in adults who are 50 years old or more.
According to the company, the first pneumococcal conjugate has potential to help address high incidence of pneumococcal pneumonia.
The application is backed by safety and immunogenicity Phase 3 trials that showed vaccination with Prevnar induced a functional antibody response to the 13 serotypes contained in the vaccine in adults 50 years of age and older.
Positive response was also seen in individuals previously vaccinated with the conventional pneumococcal polysaccharide vaccine (PPSV) and those naïve to pneumococcal vaccines.